ライフサイエンスコーパス: troponin T

1 patients for troponin I and 25 patients for troponin T).

2 .e., NT-proBNP), and cardiac necrosis (i.e., Troponin T).

3 relate with log(concomitant high-sensitivity troponin-T).

4 tients with NSTE-ACS and an elevated cardiac troponin T.

5 tality, better than high-sensitivity cardiac troponin T.

6 terminal pro-B-type natriuretic peptide, and troponin T.

7 the case of chronic HF) to high-sensitivity troponin T.

8 by a positive test for cardiac troponin I or troponin T.

9 tions as determined by expression of cardiac troponin T.

10 ned changes in pre-dialysis highly sensitive troponin T.

11 syndrome (NSTE-ACS) and an elevated cardiac troponin T.

12 tients with NSTE-ACS and an elevated cardiac troponin T.

13 ated by the significantly reduced release of troponin-T.

14 detecting low concentrations of the protein troponin-T.

15 system was developed that used thresholds of troponin T (0.05 ng/ml) and N-terminal pro-B-type natriu

16 se without (n = 43) (mean +/- SD increase in troponin T, 0.011 +/- 0.009 vs. 0.003 +/- 0.006 mug/L, P

17 21.5% with elevated high-sensitivity cardiac troponin T; 17.7% with elevated NT-proBNP) with 825 inci

18 ients with elevated high-sensitivity cardiac troponin T, 31 had signs of MI and 113 did not.

19 Levels of cardiac troponin T, a biomarker of cardiomyocyte injury, were me

20 ity C-reactive protein, and high-sensitivity troponin T, Abeta40 independently predicted CV death and

21 Adding high-sensitive cardiac troponin T absolute change to the Revised Cardiac Risk I

22 The high-sensitivity troponin T algorithm ruled out 1425 (64.1%) with a sensi

23 equivalent were 3.0 (95% CI, 2.4 to 4.3) for troponin T and 2.7 (CI, 1.9 to 4.6) for troponin I.

24 ular mortality were 3.3 (CI, 1.8 to 5.4) for troponin T and 4.2 (CI, 2.0 to 9.2) for troponin I.

25 expression of cardiomyogenic markers cardiac troponin T and alpha-smooth muscle actin in CPCedeltaB c

26 ins, including myosin light chain-2 slow and troponin T and carbonylation of myosin heavy chains.

27 easurement of the cardiac troponins, cardiac troponin T and cardiac troponin I, using sensitive metho

28 -enriched miRNAs with high-sensitive cardiac troponin T and cMyBP-C returned the highest area under t

29 the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleedin

30 High-sensitivity cardiac troponin T and creatine kinase-myocardial band were meas

31 e transcripts paralleled the rise in cardiac troponin T and decayed at 30 days.

32 is of two meat tenderisation protein markers troponin T and desmin by the four proteases was detected

33 Serum levels of troponin T and heart-type fatty acid binding protein wer

34 e 2222 patients with serial high-sensitivity troponin T and high-sensitivity troponin I measurements.

35 efficacy end point was postoperative plasma troponin T and I levels during the first 24 hours after

36 rent COVID-19 infection had higher levels of troponin T and lower lymphocyte count, but elevated D-di

37 and serial plasma levels of high-sensitivity troponin T and midregional proatrial natriuretic peptide

38 l-known biomarkers (high-sensitivity cardiac troponin T and N-terminal pro-brain natriuretic peptide)

39 pomyosin alpha-1 chain, fast myotomal muscle troponin T and parvalbumin beta 2 increased their intens

40 beating sheets of cells that express cardiac troponin T and show a full range of action potential mor

41 Troponin-T and creatine kinase-MB peaked at day 1 after

42 Ln hs-CRP elevation correlated with Ln Troponin-T and fibrinogen elevation.

43 ssociated with high plasma concentrations of troponin-T and N-terminal brain natriuretic propeptide,

44 enhancement) and biomarkers (high-sensitive troponin-T and NT-proBNP [N-terminal Pro-B-type natriure

45 The orientation of troponin-T and the troponin core domain established trop

46 Cardiac Troponins (T and I) are well established protein biomark

47 natriuretic peptide (NT-proBNP) and cardiac troponins T and I (TnT and TnI) for prognostication, but

48 omarkers of cardiac damage (high-sensitivity troponin T) and dysfunction (N-terminal pro-B-type natri

49 natriuretic peptide and/or high-sensitivity troponin T), and biventricular remodeling.

50 enaline, lipopolysaccharide binding protein, troponin T, and brain natriuretic peptide levels were me

51 d on clinical presentation, high-sensitivity troponin T, and cardiac magnetic resonance imaging, afte

52 mmetrical dimethylarginine, high-sensitivity troponin T, and cystatin C.

53 N-terminal pro-brain natriuretic peptide and Troponin T, and functional assessment comprising the 6-m

54 atriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein sign

55 atriuretic peptide, high-sensitivity cardiac troponin T, and high-sensitivity C-reactive protein.

56 nalyses, including C-reactive protein, IL-6, troponin T, and N-terminal pro-B-type natriuretic peptid

57 n, procalcitonin, ferritin, D-dimer, cardiac troponin T, and N-terminal pro-B-type natriuretic peptid

58 F: N-terminal B-type natriuretic peptide and troponin T, and newly emergent biomarkers, angiopoietin-

59 The extent of Ln hs-CRP, Ln Troponin-T, and fibrinogen elevation predicted early AF

60 Elevated levels of NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15 identif

61 riuretic peptide (NT-proBNP), high-sensitive troponin-T, and growth-differentiation factor 15 with ca

62 arker measurement (NT-proBNP, high-sensitive troponin-T, and growth-differentiation factor 15) at the

63 rapid fall in pH, and rise in blood lactate, troponin-T, and potassium.

64 f N-terminal pro-B-type natriuretic peptide, troponin-T, and urinary albumin excretion, increasing mo

65 iuretic peptide and high-sensitivity cardiac troponin T are frequently elevated in severe sepsis or s

66 in natriuretic peptide]), and myocyte death (troponin T) are related to anemia in HFrEF.

67 rence limit for the high-sensitivity cardiac troponin T assay (hs-cTnT) in 3 large independent cohort

68 The TRAPID-AMI trial study (High-Sensitivity Troponin-T Assay for Rapid Rule-Out of Acute Myocardial

69 the widespread use of high-sensitive cardiac troponin T assays, positive tests become frequent, but t

70 urve for the high-sensitivity assay of serum troponin T at 72 hours), inotrope score (calculated from

71 stable angina (28% of patients) and negative Troponin T at baseline to 3 groups: 2 groups received RI

72 h-sensitivity troponin I or high-sensitivity troponin T at presentation and after early or late seria

73 val incremental change of the ln-transformed troponin-T at 72 h was 0.79 +/- 1.54 in the xenon group

74 Postarrival incremental change in troponin-T at 72 hours was significantly less in the Xen

75 as by detecting different concentrations of Troponin T biomarkers (cTnT) through antibody-functional

76 reduced the heart recipient plasma levels of troponin T by 34% (14 900 +/- 12 100 ng/L to 9800 +/- 79

77 L and a perioperative high-sensitive cardiac troponin T change greater than or equal to 6.3 ng/L are

78 k predictive power of high-sensitive cardiac troponin T change in addition to the Revised Cardiac Ris

79 uretic peptide) and hs-TnT (high-sensitivity troponin T), circulating SN levels declined after resusc

80 osite end point in patients with an abnormal troponin T concentration (>/=14 ng per liter) as compare

81 liter) as compared with those with a normal troponin T concentration (<14 ng per liter).

82 We tested for an association between the troponin T concentration and a composite end point of de

83 We measured the cardiac troponin T concentration at baseline with a high-sensiti

84 integrate the high-sensitivity troponin I or troponin T concentration at emergency department present

85 The cardiac troponin T concentration was an independent predictor of

86 7 (99.6%) had detectable (>/=3 ng per liter) troponin T concentrations and 897 (39.3%) had abnormal t

87 7.1% among the patients who had had abnormal troponin T concentrations at baseline, as compared with

88 concentrations and 897 (39.3%) had abnormal troponin T concentrations at baseline.

89 pro-B-type natriuretic peptide, and cardiac troponin T concentrations in multivariate analyses.

90 osite end point among patients with abnormal troponin T concentrations was 1.85 (95% confidence inter

91 riuretic peptide or high-sensitivity cardiac troponin T concentrations were independently associated

92 Plasma troponin T concentrations were prospectively collected w

93 Among patients with abnormal troponin T concentrations, random assignment to prompt r

94 2.9% among those who had had normal baseline troponin T concentrations.

95 ype natriuretic peptide and high-sensitivity troponin T concentrations.

96 log-transformed concomitant high-sensitivity troponin-T concentrations (mixed linear model: t = 3.8,

97 ating best with concomitant high-sensitivity troponin-T concentrations.

98 Using Troponin T-Cre;CyclinA2-LacZ-EGFP mice, we examined card

99 flammatory markers included high-sensitivity troponin T, creatine kinase, myoglobin, N-terminal B-typ

100 igh-sensitivity C-reactive protein (hs-CRP), Troponin-T, creatine kinase-MB, fibrinogen, and D-Dimer

101 c acute cardiac stress (by measuring cardiac troponin T (cTnT) and N-terminal prohormone of brain nat

102 However, it is not clear whether cardiac troponin T (cTnT) and troponin I (cTnI) are equivalent m

103 Abstract Cardiac troponin T (cTnT) has a highly acidic extended N-terminu

104 biological significance of elevated cardiac troponin T (cTnT) in patients with neuromuscular disease

105 Changes in cardiac troponin T (cTnT) levels are required for the diagnosis

106 assumption that chronically elevated cardiac troponin T (cTnT) levels fluctuate randomly around a hom

107 Elevated plasma cardiac troponin T (cTnT) levels in patients with neuromuscular

108 p device provides the capability for cardiac-troponin T (cTnT) measurements with co-existed 10 microg

109 hypertrophic cardiomyopathy-causing cardiac troponin T (cTnT) mutation Delta160Glu (Delta160E) is lo

110 n a screen-printed electrode for the cardiac troponin T (cTnT) was developed.

111 udy was to evaluate whether elevated cardiac troponin T (cTnT) was independently associated with an i

112 ry are cardiac troponin I (cTnI) and cardiac troponin T (cTnT) which have been considered as 'gold st

113 lacrylamide (PNIPAAm) functionalised cardiac troponin T (cTnT) with anti-cTnT.

114 of TNNT2, the gene that encodes for cardiac troponin T (cTnT), a biomarker of myocardial injury.

115 tion between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B-type na

116 ide (NT-proBNP) and high-sensitivity cardiac troponin T (cTnT), and genetic analysis.

117 Cardiac troponin T (cTnT), even at low concentrations, is a risk

118 For the first time, we show that cardiac troponin T (cTnT), in part through its intrinsically dis

119 MYG), bovine serum albumin (BSA) and cardiac troponin T (cTnT), respectively.

120 eric/cooperative mechanism is cardiac muscle troponin T (cTnT), the central region (CR) and the T2 re

121 5, or that of the myocardial marker, cardiac troponin T (cTnT).

122 farction, especially with the use of cardiac troponin T (cTnT).

123 factor-15 (GDF-15), high-sensitivity cardiac troponin T (cTnT-hs) and haemoglobin, age, and previous

124 ing of cardiac Troponin-I (cTnI) and cardiac-Troponin-T (cTnT) in a point-of-care sensor format.

125 rix metalloproteinase-9 (MMP-9), and cardiac Troponin-T (cTnT) were evaluated by appropriate biochemi

126 the detection and quantification of cardiac Troponin-T (cTnT).

127 Pretransplant cardiac troponin T(cTnT(pre) ) is a significant predictor of sur

128 ve, the area under the 72-h high-sensitivity troponin-T curve was lower in patients assigned to the h

129 was the area under the 72-h high-sensitivity troponin-T curve.

130 LD had higher collagen solubility, troponin-T degradation products and glycogen content tha

131 d cellular consequences of a DCM mutation in troponin-T, DeltaK210.

132 utcomes among patients with newly recognized troponin T elevation will require an evolution in manage

133 1-h algorithm using high-sensitivity cardiac troponin T embedded in routine clinical care and its ass

134 The sensitivity of troponin T for ACS diagnosis ranged from 71% to 100%, an

135 ificantly from those of fast skeletal muscle troponin T (fsTnT).

136 gh impedance spectroscopy was used to detect troponin-T functionalized immunoassays on nanotextured Z

137 d syndrome and long-QT syndrome, and cardiac troponin T gene, tnnt2, affected in human cardiomyopathi

138 A preoperative high-sensitive cardiac troponin T greater than or equal to 17.8 ng/L and a peri

139 perienced an event associated with a cardiac troponin T >99th percentile of a normal reference popula

140 ension and a composite of myocardial injury (troponin T >= 0.03 ng/mL without nonischemic cause) and

141 al of 5460 patients had at least one cardiac troponin T >=0.01 ng/mL; 1365 of these patients were cla

142 myocardial injury (high-sensitivity cardiac troponin T >=6 ng/L] and stress (N-terminal pro-B-type n

143 proBNP (>14 pmol/L), elevated high-sensitive troponin-T (>14 ng/L), and elevated growth-differentiati

144 ro-B-type natriuretic peptide [>40 pg/mL] or troponin T [>0.6 pg/mL]) were recruited, along with 61 a

145 Troponin-T, high-sensitive C-reactive protein, urinary a

146 uretic peptide, and high-sensitivity cardiac troponin T, higher levels of Cp were associated with HF

147 r circulation and a high-sensitivity cardiac troponin T (hs-cTnT) acquired on the day of admission.

148 High-sensitivity cardiac troponin T (hs-cTnT) and N-terminal B-type natriuretic p

149 h small elevations of high-sensitive cardiac troponin T (hs-cTnT) are associated with incident heart

150 High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes used to rapidly rule

151 evel, with elevated high-sensitivity cardiac troponin T (hs-cTnT) concentrations (>/=14 ng/L) using P

152 ide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) concentrations were measured by ele

153 c value of baseline high-sensitivity cardiac troponin T (hs-cTnT) elevation in SCAD patients undergoi

154 o mental stress and high-sensitivity cardiac troponin T (hs-cTnT) in healthy older individuals withou

155 cremental prognostic value of high-sensitive troponin T (hs-cTnT) in heart failure (HF) beyond that o

156 ions of introducing high-sensitivity cardiac troponin T (hs-cTnT) into clinical practice and to defin

157 High-sensitivity cardiac troponin T (hs-cTnT) is a biomarker of cardiovascular ri

158 etectable (<5 ng/l) high-sensitivity cardiac troponin T (hs-cTnT) level and an electrocardiogram (ECG

159 that any detectable high-sensitivity cardiac troponin T (hs-cTnT) level is associated with adverse ou

160 eferable when using high-sensitivity cardiac troponin T (hs-cTnT) levels in the diagnosis of acute my

161 Their high-sensitivity cardiac troponin T (hs-cTnT) levels were measured.

162 endpoints included high-sensitivity cardiac troponin T (hs-cTnT) on day 4, left ventricular (LV) rem

163 elevated levels of high-sensitivity cardiac troponin T (hs-cTnT) or N-terminal pro-B-type natriureti

164 ority of a 0/1-hour high-sensitivity cardiac troponin T (hs-cTnT) protocol in comparison with a 0/3-h

165 ssessed by elevated high-sensitivity cardiac troponin T (hs-cTnT) test results.

166 algorithm based on high-sensitivity cardiac troponin T (hs-cTnT) testing at presentation and again 1

167 we assessed whether high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial

168 atriuretic peptide, high-sensitivity cardiac troponin T (hs-cTnT), and high-sensitivity cardiac tropo

169 eptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein choles

170 ssessed by elevated high-sensitivity cardiac Troponin T (hs-cTnT).

171 High-sensitivity troponin T (hs-TnT) and N-terminal prohormone of brain n

172 High-sensitivity troponin T (hs-TnT) assays promise greater discriminatio

173 tic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) can be used as surrogate markers and

174 The prognostic value of high-sensitivity troponin T (hs-TnT) elevation after elective percutaneou

175 the prevalence of elevated high-sensitivity troponin T (hs-TnT) in 298 patients with heart failure w

176 ate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors

177 trasensitive tests to measure high-sensitive troponin T (hs-TnT) serum levels revealed the presence o

178 elationship between OSA and high-sensitivity troponin T (hs-TnT), cardiac structure, and CV outcomes

179 he prognostic importance of high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic pe

180 merit with that of high-sensitivity cardiac troponin T (hs-TnT).

181 farction) evaluated high-sensitivity cardiac troponin-T (hs-cTnT) in a 1-hour acute myocardial infarc

182 rdial damage (using high-sensitivity cardiac troponin-T [hs-cTnT]) and with coronary heart disease (C

183 High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic

184 nknown if evaluation with a high-sensitivity troponin T (hsTnT) assay affects prognosis in this large

185 High-sensitivity troponin T (hsTNT) assays have been recently shown to pr

186 B-type natriuretic peptide, high sensitivity troponin T (hsTnT), beta-trace protein (BTP) and interle

187 atients, analyzing baseline high-sensitivity troponin T (hsTnT), NT-proBNP (N-terminal B-type natriur

188 retic peptide (NTproBNP), and high-sensitive troponin T (hsTNT).

189 to determine whether hsTnT (high-sensitivity troponin T) identifies emergency department acute heart

190 of the patients and high-sensitivity cardiac troponin T in 84.5%, with higher concentrations in those

191 ial measurements of high-sensitivity cardiac troponin T in clinical routine.

192 mited to the use of natriuretic peptides and troponin-T in patients with increased cardiovascular ris

193 ined as an absolute high-sensitivity cardiac troponin T increase of >/=14 ng/L from preoperative to p

194 ease significantly over time, troponin I and troponin T increased moderately, and no consistent clini

195 ts for troponin I and long-term outcomes for troponin T (insufficient SOE).

196 For a third trait, cardiac troponin T, investigation of regulatory domains identifi

197 Twelve-hour troponin T, left ventricular ejection fraction, and perc

198 confidence limits (CL): 1.52 to 12.30), peak troponin T level (OR: 1.20; 95% CL: 1.08 to 1.34), and u

199 Bleeding event, peak troponin T level, and peripheral vascular disease predic

200 vel, hemoglobin A1c level, phosphorus level, troponin T level, log N-terminal pro-B-type natriuretic

201 nd-point was the proportion of patients with Troponin T levels >3xULN postprocedure (at 6 or 18-24 ho

202 hest pain, elevated high-sensitivity cardiac troponin T levels (>14 ng/l), and inconclusive electroca

203 Serum high-sensitivity cardiac troponin T levels and electrocardiograms were obtained e

204 However, changes in cardiac troponin T levels during the infusion did not differ bet

205 study was to examine the extent of change in troponin T levels in patients with non-ST-segment elevat

206 yte, creatinine, creatine phosphokinase, and troponin T levels were normal.

207 patients with NSTE-ACS and elevated cardiac troponin T levels, an early invasive strategy has no ben

208 nfarct size (P<0.005) and a 61% reduction in troponin-T levels (P<0.05) in comparison with saline con

209 Troponin-T levels were measured at hospital admission, a

210 iomarkers (hs-cTnT (high sensitivity cardiac troponin-T) <6 ng/L and NT-proBNP (N-terminal pro-B-type

211 We also reconstituted mouse cardiac troponin T (McTnT) N-terminal deletion mutants, McTnT(1-

212 edural increases of high-sensitivity cardiac troponin T (mean: 9.9 ng/ml, range: 2.7 to 19.0 ng/ml vs

213 High levels of cardiac troponin T, measured by a highly sensitive assay (hs-cTn

214 rdiography, and concomitant high-sensitivity troponin-T measurement in patients with severe sepsis or

215 24-hour postoperative high-sensitive cardiac troponin T measurements and the respective changes were

216 tigations including high-sensitivity cardiac troponin T measurements at later time points or coronary

217 re- and postoperative high-sensitive cardiac troponin T measurements demonstrated a majority of patie

218 6) with troponin I and 21.4% (n = 7319) with troponin T measurements.

219 Troponin-T measurements were available from 54 xenon pat

220 cardiograms and concomitant high-sensitivity troponin-T measurements were performed in a cohort of 10

221 In addition, two mouse cardiac troponin T mutants (TnT(1-44Delta) and TnT(45-74Delta))

222 in vivo, transgenic mice harboring the R92Q troponin-T mutation and wild-type littermates received a

223 f Drosophila cardiac tubes revealed that the troponin-T mutation prolongs systole and restricts diast

224 positive for the cardiac markers troponin I, troponin T, myosin heavy chain, and connexin-43.

225 Measures: Concentrations of high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, a

226 cacy International Trial]), high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, g

227 biomarkers of cardiac damage were measured (troponin T, N-terminal pro-brain natriuretic peptide, an

228 white blood cell count, fibrinogen, D-dimer, troponin T, N-terminal pro-brain natriuretic peptide, an

229 out either elevated high-sensitivity cardiac troponin T or NT-proBNP had a 10-year CV incidence rate

230 Elevations in high-sensitivity cardiac troponin T or NT-proBNP identify individuals with elevat

231 ence laboratory) measures of troponin level (troponin T or troponin I, as available).

232 erences in creatine kinase release (P=0.92), troponin T (P=0.85), or cardiac MRI-assessed infarct siz

233 MVO patients had higher troponin T peak (P<0.0001), larger late gadolinium enhan

234 In contrast, patients with NR had higher troponin T peak (P=0.006) but similar late gadolinium en

235 TPase, increased levels of phospholamban and troponin T phosphorylation, and reduced phosphorylation

236 Concomitant high-sensitivity troponin-T predicted mortality in univariate analysis (W

237 lective expression of EcSOD from the cardiac troponin-T promoter after systemic administration of AAV

238 The troponin-T promoter restricted gene expression largely t

239 superoxide dismutase (EcSOD) via the cardiac troponin-T promoter would protect the mouse heart agains

240 in the gene TNNT2, which encodes the cardiac troponin T protein itself.

241 hs-TnI and high-sensitivity troponin T provide complementary rather than redundant i

242 in natriuretic peptide (R=0.69, P<0.001) and Troponin T (R=0.53, P=0.006).

243 rates in fully reconstituted WT and cardiac troponin T R92L and R92W thin filaments.

244 ed 2 mouse models of sarcomeric HCM (cardiac troponin T R92L and R92W) with differential myocellular

245 y outcomes included infarct size assessed by troponin T release and by cardiac MRI on day 2.

246 ylprednisolone significantly reduced cardiac troponin T release and the number of allograft infiltrat

247 myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac allograf

248 m21G6 significantly reduced infarct size and troponin-T release, and led to marked preservation of ca

249 All available cases were analyzed for troponin-T release.

250 markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepa

251 The binding of troponin T's N terminus to the actin-mutant tropomyosin

252 n natriuretic peptide (pro-BNP), and cardiac troponin T showed significant linear trends for increase

253 The total loss of slow skeletal muscle troponin T (ssTnT encoded by TNNT1 gene) due to a nonsen

254 he truncated slow skeletal muscle isoform of troponin T (ssTnT) encoded by the mutant TNNT1 gene is u

255 encodes the slow skeletal muscle isoform of troponin T (ssTnT).

256 y more cardiomyocytes, determined by cardiac troponin-T staining, in the MI zone of the QHG213H hydro

257 dysfunction), age, injury (high-sensitivity troponin T), systemic involvement, and electrical abnorm

258 myocardial perfusion imaging after negative troponin T tests and nondiagnostic ECGs.

259 tween or near residues 112 to 136 of cardiac troponin-T, the crucial TnT1 (N-terminal domain of tropo

260 oding cardiac troponin I (TNNI3) and cardiac troponin T (TNNT2) caused altered troponin protein stoic

261 cluding the Insulin Receptor (Insr), Cardiac Troponin T (Tnnt2), Lim Domain Binding 3 (Ldb3) RNAs in

262 roponin I (TNNI3p.98truncation ) and cardiac troponin T (TNNT2p.K217deletion ; also known as the p.K2

263 The independent predictive value of troponin T (TNT) after on-pump cardiac surgery was estab

264 Cardiac troponin T (TnT) is a highly sensitive cardiac biomarker

265 Troponin T (TnT) is the thin-filament-anchoring subunit

266 Three troponin T (TnT) mutants that cause hypertrophic, restri

267 In this study, polymer imprinted with troponin T (TnT) was assessed using electrochemical meth

268 The C-terminal region of cardiac troponin T (TnT), a tropomyosin-associated protein, is r

269 The interference effect of troponin T (TnT), bovine serum albumin (BSA) and myoglob

270 als also showed negligible interference from troponin T (TnT), bovine serum albumin (BSA) and urea un

271 The N-terminal half of troponin T (TnT), TNT1, independently promotes tropomyos

272 ith a dilated cardiomyopathy (DCM) mutation, troponin T (TnT)-R173W, display sarcomere protein misali

273 its, troponin C (TnC), troponin I (TnI), and troponin T (TnT).

274 tions in the TNNT2 gene that encodes cardiac troponin T (TnT).

275 ced expression of troponin I to 39% and 51%, troponin T to 64% and 53%, and troponin C to 73% and 97%

276 the binding of increasing concentrations of troponin-T to the immobilized antibodies on the ZnO surf

277 in-T, the crucial TnT1 (N-terminal domain of troponin-T)-tropomyosin-binding region, cause cardiomyop

278 -pro-B-type natriuretic peptide (NT-proBNP), troponin T (TropT) and C-reactive protein (CRP) predict

279 rrest of cardiomyocyte contraction either by troponin T type 2a (tnnt2a) MO or in weak atriumm58 (wea

280 An abnormal troponin T value of 14 ng per liter or higher did not id

281 diovascular disease in our study had cardiac troponin T values above the current myocardial infarctio

282 The effect of xenon on the change in the troponin-T values did not differ in patients with or wit

283 Elevated high-sensitivity troponin T was associated with an increased risk of card

284 Troponin T was elevated in a substantial number of patie

285 Highly sensitive troponin T was lower at follow up (Baseline 38.8 pg/L, f

286 High-sensitivity cardiac troponin T was measured as a marker of myocardial injury

287 A periprocedural increase in troponin T was observed in 3.2% of the CHF procedures, i

288 The level of high-sensitive cardiac troponin T was significantly associated with preexisting

289 Troponin T was significantly increased in blood, and ech

290 The release of troponin-T was determined at arrival to hospital and at

291 Enhanced detection of troponin-T was found to correlate to the oxygen vacancie

292 Elevated levels of troponin I or troponin T were associated with higher risk for short-te

293 iuretic peptide and high-sensitivity cardiac troponin T were measured 1, 2, and 7 days after enrollme

294 hs-TnI and high-sensitivity troponin T were only modestly correlated ( r=0.47) and w

295 ntricular structure and function and cardiac troponin-T were among the top predictors for incident he

296 We measured cardiac troponin T with a highly sensitive assay (hs-cTnT) at 2

297 e association of hs-TnI and high-sensitivity troponin T with incident CVD events was also evaluated.

298 ro-brain natriuretic peptide (NT-proBNP) and troponin T with liver involvement and the presence of ne

299 t patients would have had a negative cardiac troponin T with older assays); and Group 4, those with h

300 re- and postoperative high-sensitive cardiac troponin T with the occurrence of major adverse cardiac